logo
ChatGPT can now ‘think' and ‘act' for you after a new update

ChatGPT can now ‘think' and ‘act' for you after a new update

CNN17-07-2025
OpenAI on Thursday announced a new feature for ChatGPT that allows the popular chatbot to execute actions on a user's behalf. It's part of an industry-wide push to change the way people get things done on the Internet: Tech giants hope that instead of bouncing between apps and manually searching the web, users might be able to one day rely on agents to do it all.
ChatGPT's new agent mode, which begins rolling out immediately, is another sign that tech giants are doubling down on digital helpers that demonstrate significantly advanced capabilities. It also heightens the race between OpenAI and Google, which is pursuing similar ambitions with its Gemini helper.
OpenAI said on Thursday that ChatGPT's new agent mode 'thinks' and 'acts' using its own virtual computer, enabling it to handle complex action-oriented requests. For example, users will be able to issue command such as 'look at my calendar and brief me on upcoming client meetings based on recent news' or 'plan and buy ingredients to make Japanese breakfast for four,' the company said in a blog post.
In a video demonstration, OpenAI employees wrote a long and detailed prompt asking the agent to help the user prepare for a wedding. It included a set of specific instructions such as 'find an outfit that matches the dress code,' adding that it should propose five options, along with hotels that can accommodate a couple of buffer days around the event.
The new feature is available for those who subscribe to a Pro, Plus or Team plan. It builds on and combines capabilities from the ChatGPT Operator and Deep Research tools OpenAI already offers; Operator browses the web, while Deep Research analyzes online resources to do things like compile reports.
The update is another step in OpenAI's efforts to turn ChatGPT in a more comprehensive universal assistant. At the same time, the broader AI industry is also grappling with how to address important shortcomings and privacy concerns around the technology. AI models are still prone to hallucinations and bias and can act in unpredictable ways, as xAI's Grok chatbot demonstrated last week when it spewed antisemitic content after being prompted to do so.
In a blog post, OpenAI acknowledged that ChatGPT's new functionality presents new risks. It said it has limited the data the model has access to, and certain tasks – like sending an email – require the user's oversight. The model is also trained to refuse 'high-risk tasks' like bank transfers, the company says.
'I would explain this to my own family as cutting edge and experimental; a chance to try the future, but not something I'd yet use for high-stakes uses or with a lot of personal information until we have a chance to study and improve it in the wild,' OpenAI CEO Sam Altman said in a post on X announcing the agent.
He advised users to be cautious when giving ChatGPT access to personal information. For example, granting access to a calendar to coordinate a group dinner might make sense, but the agent wouldn't need calendar access to shop for clothes on a user's behalf.
The announcement comes as tech giants are increasingly pushing to develop AI agents as they seek to win the AI race. Google made a flurry of AI-related announcements during its developer conference in May, including an agent that can make restaurant reservations and buy event tickets, among other tasks. Apple is working on a more advanced version of Siri that can use apps on a user's behalf, although that update is delayed indefinitely.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cardinal Health expands urology focus with $1.9bn Solaris Health deal
Cardinal Health expands urology focus with $1.9bn Solaris Health deal

Yahoo

time21 minutes ago

  • Yahoo

Cardinal Health expands urology focus with $1.9bn Solaris Health deal

US drug distributor Cardinal Health has signed a $1.9bn agreement to acquire a majority stake in Solaris Health from Lee Equity Partners. The deal aims to expand the Specialty Alliance, the distributor's multi-speciality management services organisation (MSO) platform, in which Cardinal will gain a stake of around 75%. The acquisition will also create the Urology Alliance, comprising a collaborative network of urology providers within Cardinal's Specialty Alliance MSO, as well as resonate with plans to expand the delivery of urological patient care. Cardinal's Solaris buyout complements its recent acquisitions of Urology America, Potomac Urology, and Academic Urology & Urogynaecology, signalling its urologic strategy. The transaction is expected to be completed by the end of this year, pending customary closing conditions. Cardinal Health CEO Jason Hollar stated that growing the Speciality Alliance is a 'top priority' for the company, with the latest urology purchase leaving it 'well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of the Specialty Alliance, Specialty Networks and Cardinal Health'. Research indicates there is a shortage of urologists in the US, with 62% of US counties lacking a practising urologist and just one new urologist entering the field for every ten retiring. The figures lead to challenges in the broader field, including delayed diagnoses, increased rates of advanced-stage conditions, and significant health disparities, with these particularly pronounced in rural communities. GlobalData's senior medical analyst Selena Yu foresees Cardinal's acquisition as reflecting a shift from drug distribution with a 'lower profit margin, towards higher margin speciality care in urology'. Yu said: 'MSOs help streamline backend work like billing and staffing to allow for physicians to focus on care. 'Additionally, with a large network of specialists, patients can receive care in the same region by different care specialists, which will reduce wait times and improve care continuity. Additionally, the Cardinal Health Alliance has other specialities like oncology specialists, which makes referrals more streamlined.' Cardinal's acquisition coincided with the release of its Q4 2025 financials. The company's profits per share came in at $2.08, beating the forecasted $2.03, yet profits for the quarter came in at $60.2bn, below the $60.92bn forecast, prompting a pre-market stock drop of more than 11% on 12 August. Cardinal's share price has since recovered to a drop of around 6% to $147.05 per share, down from $157.66 per share at market close on 11 August. "Cardinal Health expands urology focus with $1.9bn Solaris Health deal" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Effettua l'accesso per consultare il tuo portafoglio

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications
Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

Yahoo

time21 minutes ago

  • Yahoo

Texas sues Eli Lilly for allegedly bribing providers to prescribe its medications

WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its medications. The attorney general's office said in a statement that the company bribed and illegally induced medical providers to prescribe its most profitable drugs, including the GLP-1 medications Mounjaro and Zepbound, used for weight loss and diabetes treatment. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Attorney General Paxton said. The lawsuit builds upon Attorney General's previous legal action to hold drug manufacturers accountable for fraud and abuse, the statement added. Last year, Paxton had sued insulin manufacturers, including Lilly and pharmacy benefit managers (PBMs), alleging that manufacturers artificially raised the prices of insulin and then paid a significant, undisclosed portion back to the PBMs for preferential treatment in return. Eli Lilly did not immediately respond to a Reuters request for comment. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut
Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut

Yahoo

time21 minutes ago

  • Yahoo

Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut

President Donald Trump has signaled he may be open to letting Nvidia (NASDAQ:NVDA) ship a toned-down version of its most advanced Blackwell AI chip to China if the company trims its capabilities by 30% to 50%. The comment comes shortly after Trump confirmed an unusual arrangement already in place for Nvidia's less-powerful H20 chip, which allows exports to China in exchange for a 15% revenue share paid directly to the US government. Advanced Micro Devices will follow the same formula for its MI308 chip, according to a person familiar with the matter. Nvidia has not commented on the president's remarks. Warning! GuruFocus has detected 5 Warning Signs with NVDA. The potential deal for Blackwell would mirror Trump's broader push to secure financial returns for the US in exchange for loosening certain export restrictions a strategy that could influence how American companies negotiate market access in China. While Trump didn't outline a specific timeline, he suggested Nvidia CEO Jensen Huang could soon meet with him to discuss a negatively enhanced Blackwell variant. If approved, the move could mark a shift in how high-end US chip technology is selectively offered abroad. Nvidia's Blackwell chips are the backbone of today's most powerful AI systems but remain off-limits to China under current US rules. Both Nvidia and AMD (NASDAQ:AMD) have taken revenue hits as tighter controls limited exports to older models on par with domestic Chinese alternatives products that have struggled to gain traction. Nvidia has already said it is developing another China-specific chip and will seek approval to sell it. The company noted that further cutting back its Hopper-based H20 chip is no longer viable, suggesting a modified Blackwell could be the clearest path to regaining momentum in one of the world's largest AI markets. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store